Link Pharma Chem Ltd
Link Pharma Chem Ltd (LINKPH) last reported results for the quarter ended Jun 2026, with sales of ₹8.77 crore and net profit of ₹0.32 crore. The stock last traded at ₹26.3, a market capitalisation of ₹11.7 crore. Over the past 52 weeks the stock has ranged between ₹21 and ₹38. Figures are as of 6 Oct 2026 and are not real time.
Link Pharma Chem Ltd share price and key metrics
- Current price
- ₹26.3
- Market cap
- ₹11.7 cr
- Book value
- ₹28.8
- ROE
- 0.63%
- ROCE
- 3.48%
- Dividend yield
- 0.00%
- 52w high / low
- 38.0/21.0
Metrics as of 6 Oct 2026. Not real time.
Track Link Pharma Chem Ltd
Cruxal reads every Link Pharma Chem Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Link Pharma Chem Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- -5%
- 3 Years
- -11%
- TTM
- 16%
- 10 Years
- 7%
- 5 Years
- -42%
- 3 Years
- -48%
- TTM
- 100%
- 10 Years
- 7%
- 5 Years
- -6%
- 3 Years
- -17%
- 1 Year
- -25%
- 10 Years
- 4%
- 5 Years
- -1%
- 3 Years
- -6%
- Last Year
- 1%
Link Pharma Chem Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹8.77 cr, up 12.3% from ₹7.81 cr a year earlier. Net profit was ₹0.32 cr, down 20.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4.8 | 5.34 | 6.45 | 7.81 | 6.29 | 6.73 | 6.59 | 8.77 |
| Expenses | 5.1 | 5.23 | 6.68 | 7.17 | 5.95 | 6.04 | 6.83 | 8.32 |
| Operating profit | -0.3 | 0.11 | -0.23 | 0.64 | 0.34 | 0.69 | -0.24 | 0.45 |
| OPM % | -6.25% | 2.06% | -3.57% | 8.19% | 5.41% | 10.25% | -3.64% | 5.13% |
| Other income | 0.36 | -0.56 | 0.12 | 0.21 | 0.05 | -0.2 | 0.15 | 0.35 |
| Interest | 0.21 | 0.21 | 0.14 | 0.1 | 0.13 | 0.14 | 0.15 | 0.14 |
| Depreciation | 0.24 | 0.24 | 0.24 | 0.24 | 0.25 | 0.25 | 0.25 | 0.27 |
| Profit before tax | -0.39 | -0.9 | -0.49 | 0.51 | 0.01 | 0.1 | -0.49 | 0.39 |
| Tax % | -20.51% | -24.44% | -26.53% | 21.57% | 0.00% | 40.00% | -16.33% | 17.95% |
| Net profit | -0.31 | -0.67 | -0.35 | 0.4 | 0.02 | 0.07 | -0.41 | 0.32 |
| EPS (₹) | -0.70 | -1.51 | -0.79 | 0.90 | 0.05 | 0.16 | -0.92 | 0.72 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Link Pharma Chem Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.1 | 23.53 | 24.5 | 25.47 | 34.81 | 53.56 | 38.76 | 29.9 | 25.43 | 27.43 | 28.38 |
| Operating profit | 2.54 | 2.78 | 2.02 | 3.42 | 3.14 | 3.54 | 2.72 | -0.65 | 0.13 | 1.45 | 1.24 |
| OPM % | 15.78% | 11.81% | 8.24% | 13.43% | 9.02% | 6.61% | 7.02% | -2.17% | 0.51% | 5.29% | 4.37% |
| Net profit | 0.23 | 1.13 | 0.66 | 0.95 | 1.08 | 1.88 | 0.65 | -1.36 | -1.03 | 0.08 | 0 |
| EPS (₹) | 0.52 | 2.54 | 1.49 | 2.14 | 2.43 | 4.23 | 1.46 | -3.06 | -2.32 | 0.18 | 0.01 |
TTM is the trailing twelve months to the most recent quarter.
Link Pharma Chem Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 |
| Reserves | 4.16 | 5.35 | 5.94 | 6.99 | 8.12 | 10.03 | 10.60 | 9.27 | 8.22 | 8.35 |
| Borrowings | 4.73 | 2.71 | 2.64 | 3.56 | 3.66 | 6.39 | 8.76 | 9.22 | 5.78 | 7.31 |
| Other liabilities | 3.81 | 4.69 | 4.99 | 3.98 | 9.82 | 8.10 | 8.66 | 3.02 | 4.86 | 4.87 |
| Total liabilities | 17.14 | 17.19 | 18.01 | 18.97 | 26.04 | 28.96 | 32.46 | 25.95 | 23.30 | 24.97 |
| Fixed assets | 9.57 | 9.76 | 9.14 | 8.81 | 8.71 | 8.79 | 9.00 | 9.94 | 9.28 | 10.38 |
| CWIP | 0.00 | 0.01 | 0.43 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 4.52 | 3.64 | 2.93 | 2.06 | 2.47 |
| Other assets | 7.54 | 7.39 | 8.41 | 10.13 | 17.30 | 15.44 | 19.82 | 13.08 | 11.96 | 12.12 |
| Total assets | 17.14 | 17.19 | 18.01 | 18.97 | 26.04 | 28.96 | 32.46 | 25.95 | 23.30 | 24.97 |
As reported by the company. Total assets equal total liabilities by construction.
Link Pharma Chem Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2.23 | 3.79 | 1.36 | 2.95 | 4.84 | -1.26 | -1.71 | -0.03 | 2.69 | 2.15 |
| Cash from investing | -0.73 | -1.15 | -0.96 | -1.66 | -2.16 | -4.97 | -0.08 | 0.41 | 1.53 | -2.66 |
| Cash from financing | -1.48 | -2.63 | -0.46 | 0.55 | -0.33 | 2.27 | 1.61 | -0.41 | -4.21 | 0.99 |
| Net cash flow | 0.02 | 0.00 | -0.05 | 1.85 | 2.35 | -3.95 | -0.17 | -0.03 | 0.00 | 0.48 |
| Free cash flow | 1.37 | 2.63 | 0.49 | 1.27 | 3.13 | -2.01 | -2.60 | -0.86 | 2.43 | 0.05 |
| CFO / operating profit | 92% | 147% | 77% | 83% | 169% | -17% | -48% | -52% | 2,046% | 150% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Link Pharma Chem Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 13.00% | 15.41% | 10.34% | 18.71% | 14.61% | 13.16% | 6.72% | -4.79% | -3.00% | 3.48% |
| Debtor days | 49.42 | 49.33 | 45.29 | 71.51 | 58.19 | 36.60 | 34.18 | 62.87 | 72.05 | 70.26 |
| Inventory days | 285.97 | 96.96 | 92.54 | 60.04 | 51.35 | 47.68 | 209.23 | 135.89 | 166.94 | 170.29 |
| Days payable | 202.93 | 124.25 | 108.98 | 110.86 | 140.70 | 45.37 | 112.90 | 38.51 | 101.21 | 110.59 |
| Cash conversion cycle | 132.47 | 22.05 | 28.85 | 20.68 | -31.16 | 38.90 | 130.51 | 160.24 | 137.78 | 129.96 |
| Working capital days | 0.23 | 31.64 | 31.43 | 51.45 | 10.49 | 14.17 | 26.74 | 5.13 | 15.07 | -7.05 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Link Pharma Chem Ltd shareholding pattern
Promoters held 52.40% at Jun 2026, up from 51.49% at Jun 2025. DIIs 0.02%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.49% | 51.49% | 51.49% | 51.49% | 51.49% | 51.49% | 52.40% | 52.40% |
| DIIs | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public | 48.49% | 48.50% | 48.49% | 48.50% | 48.49% | 48.49% | 47.59% | 47.58% |
| No. of shareholders | 6,151 | 6,181 | 6,160 | 6,112 | 6,090 | 6,063 | 6,020 | 6,005 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Link Pharma Chem Ltd corporate filings
- We hereby submit confirmation certificate received from M/s. MUFG Intime India Private Limited, RTA of the Company pursuant to Regulation 74(5) of SEBI (DP) Regulations 2018, for quarter ....Company Updatelow impact
- Intimation of Trading window closure period.Insider Trading / SASTlow impact
- Link Pharma Chem Ltd. Announces Re-appointment of Mr. Satish G. Thakur as Chairman and Whole-time DirectorCompany Updatelow impact
Cruxal's analysis: Link Pharma Chem Ltd. has formally announced the re-appointment of Mr. Satish G. Thakur…
Read the full analysis - Link Pharma Chem Ltd. announces re-appointment of Mr. Rishikesh Thakur as Managing DirectorCompany Updatelow impact
Cruxal's analysis: Link Pharma Chem Ltd. has formally announced the re-appointment of Mr. Rishikesh Thakur…
Read the full analysis - Link Pharma Chem Limited Announces Successful Conclusion of 41st Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Link Pharma Chem Limited has successfully concluded its 41st Annual General Meeting held…
Read the full analysis - Link Pharma Chem Limited Concludes 41st Annual General Meeting; Re-appoints Key Management PersonnelAGM/EGMlow impact
Cruxal's analysis: Link Pharma Chem Limited has successfully concluded its 41st Annual General Meeting held…
Read the full analysis - Link Pharma Chem Limited reports Q1 FY2027 financial results with net profit of 31.83 lakhCompany Updatehigh impact
Cruxal's analysis: Link Pharma Chem Limited has released its unaudited financial results for the quarter…
Read the full analysis - Link Pharma Chem reports turnaround in Q1 FY27 with INR 31.83 crore profit vs loss in previous quarterBoard Meetinghigh impact
Cruxal's analysis: Link Pharma Chem Limited reported a significant financial turnaround for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.